Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus

被引:50
作者
Sanders, NN
De Smedt, SC
Cheng, SH
Demeester, J
机构
[1] Univ Ghent, Gen Biochem & Phys Pharm Labs, Fac Pharm, B-9000 Ghent, Belgium
[2] Genzyme Corp, Framingham, MA 01701 USA
关键词
cystic fibrosis; gene therapy; lipoplexes; sputum; mucus;
D O I
10.1038/sj.gt.3301663
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The highly viscous secretions lining the upper airways and bronchi of cystic fibrosis (CF) patients may pose a significant barrier to successful gene therapy of the lung, In this report we examined the influence of CF mucus components (albumin, DNA, mucin and phospholipids) on the gene transfection activity of cationic DOTAP-based lipoplexes and pegylated GL67-based lipoplexes which previously have been used in CF clinical studies. Upon exposure of the cationic DOTAP:DOPE lipoplexes to either albumin, linear DNA or mucin (at concentration ratios expected to occur in vivo) a significant decrease in gene transfection activity was observed. This was primarily due to aggregation of the lipoplexes. However, exposure of pegylated GL67 lipoplexes to the same components did not affect their gene transfection activity. Indeed, it was determined that CF mucus components did not interact significantly with these pegylated GL67 lipoplexes. These results suggest that charge shielding of cationic gene carriers with pEG may favor their physicochemical stability in CF mucus and thereby aid in preserving their transfection activity.
引用
收藏
页码:363 / 371
页数:9
相关论文
共 29 条
[1]   Gene therapy for lung disease: Hype or hope? [J].
Albelda, SM ;
Wiewrodt, R ;
Zuckerman, JB .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (08) :649-660
[2]   Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis:: a double-blind placebo-controlled trial [J].
Alton, EWFW ;
Stern, M ;
Farley, R ;
Jaffe, A ;
Chadwick, SL ;
Phillips, J ;
Davies, J ;
Smith, SN ;
Browning, J ;
Davies, MG ;
Hodson, ME ;
Durham, SR ;
Li, D ;
Jeffery, PK ;
Scallan, M ;
Balfour, R ;
Eastman, SJ ;
Cheng, SH ;
Smith, AE ;
Meeker, D ;
Geddes, DM .
LANCET, 1999, 353 (9157) :947-954
[3]   SECRETED PLACENTAL ALKALINE-PHOSPHATASE - A POWERFUL NEW QUANTITATIVE INDICATOR OF GENE-EXPRESSION IN EUKARYOTIC CELLS [J].
BERGER, J ;
HAUBER, J ;
HAUBER, R ;
GEIGER, R ;
CULLEN, BR .
GENE, 1988, 66 (01) :1-10
[4]   Status of gene therapy for cystic fibrosis lung disease [J].
Boucher, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (04) :441-445
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]   Gene therapy for cystic fibrosis [J].
Davies, JC ;
Geddes, DM ;
Alton, EWFW .
JOURNAL OF GENE MEDICINE, 2001, 3 (05) :409-417
[7]   Cystic fibrosis [J].
Davis, PB ;
Drumm, M ;
Konstan, MW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (05) :1229-1256
[8]   Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro [J].
Duncan, JE ;
Whitsett, JA ;
Horowitz, AD .
HUMAN GENE THERAPY, 1997, 8 (04) :431-438
[9]   A concentrated and stable aerosol formulation of cationic Lipid: DNA complexes giving high-level gene expression in mouse lung [J].
Eastman, SJ ;
Lukason, MJ ;
Tousignant, JD ;
Murray, H ;
Lane, MD ;
StGeorge, JA ;
Akita, GY ;
Cherry, M ;
Cheng, SH ;
Scheule, RK .
HUMAN GENE THERAPY, 1997, 8 (06) :765-773
[10]  
Ernst N, 1999, J GENE MED, V1, P331, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<331::AID-JGM60>3.0.CO